- Home
- PLRX vs NOTV Comparison
PLRX vs NOTV Comparison
Compare PLRX & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- NOTV
- Stock Information
- Founded
- PLRX 2015
- NOTV 1974
- Country
- PLRX United States
- NOTV United States
- Employees
- PLRX N/A
- NOTV N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- NOTV Health Care
- Exchange
- PLRX Nasdaq
- NOTV Nasdaq
- Market Cap
- PLRX 89.0M
- NOTV 72.1M
- IPO Year
- PLRX 2020
- NOTV 1997
- Fundamental
- Price
- PLRX $1.64
- NOTV $1.69
- Analyst Decision
- PLRX Hold
- NOTV Strong Buy
- Analyst Count
- PLRX 10
- NOTV 1
- Target Price
- PLRX $3.93
- NOTV $5.00
- AVG Volume (30 Days)
- PLRX 972.5K
- NOTV 422.9K
- Earning Date
- PLRX 08-07-2025
- NOTV 08-06-2025
- Dividend Yield
- PLRX N/A
- NOTV N/A
- EPS Growth
- PLRX N/A
- NOTV N/A
- EPS
- PLRX N/A
- NOTV N/A
- Revenue
- PLRX N/A
- NOTV $505,299,000.00
- Revenue This Year
- PLRX N/A
- NOTV $5.64
- Revenue Next Year
- PLRX N/A
- NOTV $5.16
- P/E Ratio
- PLRX N/A
- NOTV N/A
- Revenue Growth
- PLRX N/A
- NOTV 0.85
- 52 Week Low
- PLRX $1.10
- NOTV $1.15
- 52 Week High
- PLRX $16.10
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- PLRX 56.62
- NOTV 42.28
- Support Level
- PLRX $1.40
- NOTV $1.67
- Resistance Level
- PLRX $1.70
- NOTV $1.85
- Average True Range (ATR)
- PLRX 0.11
- NOTV 0.13
- MACD
- PLRX 0.00
- NOTV -0.01
- Stochastic Oscillator
- PLRX 77.78
- NOTV 10.42
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.